AGORACOM Small-cap Investor Relations Blog

Global Leaders in Mobile ECG Connectivity

• 20 years of medical credibility licensing technologies to hospitals, physicians, remote patient monitoring  platforms, research groups and commercial call centers
• Sold into > 20 countries, with the largest customer base located in the US
• Class II medical device clearances and device agnostic for collecting, viewing, recording, analyzing and  storing of ECGs for management of patient and consumer health
• ECG solutions for both consumer (OTC) and medical (Rx) markets
• Owns all IP and source code
• Market expert contributor for reports in m‐health, mobile cardiac monitoring and new advances in  consumer health and wellness monitoring

Recent Highlights

• Announced ECG Services Integration and Co-Marketing Agreement with California-Based BodiMetrics LLC Read More
  
  • GEMS™ Universal will be available under two subscription models:
  • $6 US per month with one free ECG interpretation included; and,
  • $69 US per year with 12 free ECG interpretations that may be requested any time during the one year subscription.
• GEMS(TM) Universal ECG App Launched in Partnership with Multiple ECG Device Manufacturers Read More
  • GEMS™ Universal ECG app , a version of the Company’s US Food and Drug Administration cleared and Health Canada approved GEMS™ Mobile ECG app,
  • Now available for download from the Google Play store
• CardioComm Solutions’ Heartcheck(TM) CardiBeat Handheld ECG Device Cleared by Health Canada for Direct-to-Consumer Sales Read More
  • Received approval from Health Canada for the over-the-counter sales and marketing of its existing GEMS™ Mobile smartphone app and for the HeartCheck™ CardiBeat, its newest handheld heart rhythm monitor.
  • Both devices were cleared by the Food and Drug Administration in early 2019.
• CardioComm Solutions Files with Health Canada for Direct to Consumer Sales Approval of the Heartcheck(TM) Cardibeat Handheld ECG Device Read More
  • Filed with Health Canada for approval for the over-the-counter  sales and marketing of their GEMS™ Mobile smartphone app and their newest handheld, heart rhythm monitor, the HeartCheck™ CardiBeat.
  • Both were cleared by the Food and Drug Administration in early 2019 and are available for sale direct to consumers in the US.

Company Accolades

FULL DISCLOSURE: CardioComm Solutions Inc. is an advertising client of AGORA Internet Relations Corp.

Tags: EKG, mhealth, small cap stocks, stocks, tsx, tsx-v